Neglected Tropical Disease Diagnosis Trends and Forecast
The future of the global neglected tropical disease diagnosis market looks promising with opportunities in the hospital and clinic, home healthcare, and clinical laboratory markets. The global neglected tropical disease diagnosis market is expected to grow with a CAGR of 4.9% from 2024 to 2030. The major drivers for this market are escalating number of overlooked tropical diseases, rising demand for rapid diagnostic tests, and mounting recognition of NTDs.
• Lucintel forecasts that within the disease type, dengue will remain the largest segment over the forecast period due to increasing adoption of point-of-care testing for dengue virus detection in developed nations.
• Within the end use category, clinical laboratory will remain the largest segment due to increased number of laboratories across world and rising availability of advanced equipment in clinical laboratories.
• In terms of region, North America will remain the largest segment over the forecast period due to existence of skilled healthcare professionals and growing adoption of point-of-care testing services at home healthcare in the region.
Gain valuable insights for your business decisions with our comprehensive 150+ page report.
Emerging Trends in the Neglected Tropical Disease Diagnosis Market
Emerging trends in the neglected tropical disease (NTD) diagnosis market are redefining its future applications and dynamics.
• Integration of Molecular Diagnostics: Use of advanced molecular techniques such as PCR and NGS is growing rapidly. These methods have high sensitivity with high specificity enabling early accurate detection of NTDs which is important for improving their diagnosis in resource constrained healthcare areas.
• Development of Rapid Diagnostic Tests: There is an increasing emphasis on rapid diagnostic tests development that will provide results quickly without requiring much equipment. These tests can be very useful particularly in remote or low resource settings where timely diagnosis can significantly impact disease management and control.
• Digital Health inclusions: The advancement of digital health aids such as mobile applications and telemedicine is helping to increase availability and management of NTD diagnostics. This includes remote consultation, data sharing, and monitoring that improve overall healthcare delivery.
• Progresses in Point-of-Care Diagnostics: There have been new innovations in the point-of-care diagnostic devices increasing accessibility towards NTD diagnosis for underserved areas. Portable, user-friendly tools providing accurate results without extensive laboratory infrastructure are gaining importance.
• Focus on Affordable and Sustainable Solutions: There is a strong focus on sustainable diagnostic solutions that are also affordable. These efforts seek to reduce the cost of diagnostic tests and make them available in low-income settings thus addressing global inequities.
These trends reflect a shift towards more advanced, accessible, and affordable diagnostic technologies for NTDs. A combination of molecular techniques, digital health tools, and rapid diagnostics are improving disease detection and management especially in resource-poor settings.
Recent Developments in the Neglected Tropical Disease Diagnosis Market
Recent occurrences have drawn attention to ongoing innovations taking place within the neglected tropical diseases (NTDs) diagnosis market.
• Emergence of Next-Generation Sequencing (NGS): Next-generation sequencing (NGS) has emerged as an essential tool for diagnosing NTDs due to its ability to perform comprehensive pathogen analysis on many samples at once. It simultaneously detects several different NTDs from one specimen allowing detailed genetic information useful for both accurate diagnosis and tracking diseases outbreaks. Though expensive to implement or requiring specialized equipment this technology makes it ideal for research work or large-scale epidemiological studies.
• Advancements in Rapid Diagnostic Tests: This also refers to new methods that deliver faster results than before like rapid diagnostic tests (RDTs). These tests employ simple portable devices that require minimum training hence can be used in remote places with low resources. RDT advancements aim at improving its sensitivity and specificity as well as lowering costs and ease of use in real-world settings.
• Integration with Artificial Intelligence (AI): Diagnostic platforms are now including artificial intelligence for more precise results. Machine learning algorithms analyze diagnostic data, such as imaging results or molecular profiles, to identify patterns and improve diagnostic precision. By combining this information the AI-driven tools may also predict disease outbreaks and make possible individualized treatment plans which is a major milestone in the management of NTDs.
• Development of Affordable Diagnostic Solutions: There is a great call to cut down on costed diagnostics so that the poor can have access to them. Innovations include low-cost materials and simplified testing procedures which bring down production costs. The idea behind making affordable diagnostics is to ensure that there is no distinction between those from low-income areas with limited resources and others found in high-resource places thus enabling more people to access key health services.
• Growth of Mobile Health (mHealth) Integration: The integration of mobile health technologies into NTD diagnostics continues to grow. Remote diagnosis, data collection, and patient management are some of the applications for mobile apps and telemedicine platforms. This enhances remote monitoring especially where healthcare facilities are not available as well as allows real-time collaboration between patients and health caregivers.
These developments highlight significant advancements in NTD diagnostics, driven by technological innovations, cost reduction efforts, and improved accessibility. These progressions are crucial for enhancing disease detection and management in diverse settings.
Strategic Growth Opportunities for Neglected Tropical Disease Diagnosis Market
The changing situation of global health priorities as well as technological advancements means that there are several strategic opportunities within the ignored tropical disease (NTD) diagnosis sector. Addressing these opportunities calls for a focused innovation, collaboration, and market participation approach. Companies and institutions can apply these strategies to enhance their diagnostic capabilities for NTDs populations’ health improvement.
• Expansion into Low Resource Settings: There exists a great potential to create and release diagnostic equipment that are meant for low-resource settings. Such firms can address such situations by focusing on affordable, user-friendly, and rapid diagnostic devices.
• Investing in Advanced Technologies: Investing on advanced technologies such as Next-Generation Sequencing (NGS) and Artificial Intelligence (AI) is capable of leading to innovation in NTD diagnostics. By doing so, these technologies provide improved accuracy and efficiency making firms that use them be at the leading edge of advancing their diagnostic capabilities thereby enhancing their competitiveness.
• Partnerships with Global Health Organizations: Collaboration with global health organizations, non-governmental organizations, and development partners may help access funding and resources. This strategic alliance could be instrumental towards developing diagnostic tools, distributing them as well as conducting researches aimed at controlling NTDs globally.
• Development of Integrated Diagnostic Platforms: The creation of integrated diagnostic platforms comprising molecular diagnostics, rapid tests, and digital health tools can improve diagnosis processes. These platforms offer holistic solutions for detecting multiple NTDs thus providing more value to healthcare providers and patients.
• Focus on Sustainability & Cost Reduction: Emphasizing sustainability during diagnostics development including using eco-friendly materials or utilizing low cost production techniques would enhance market appeal and accessibility. Lowering prices without compromising quality will allow broader reach thus addressing prevailing health disparities.
These business expansion opportunities identify areas where progress can be achieved through innovation, partnerships, or cost-effective approaches within the NTD diagnosing industry. Pursuing these avenues would consequently simplify disease detection procedures thereby enhancing universal health care coverage towards attaining global health targets.
Neglected Tropical Disease Diagnosis Market Driver and Challenges
The market for neglected tropical diseases (NTDs) diagnosis is regarded as an essential component of global health because it focuses on recognition and control of diseases that are more prevalent among people in the low-income areas of tropical and subtropical regions. Unlike common health problems, these conditions such as leprosy, malaria, and lymphatic filariasis do not get enough attention. Thus, recognizing the driving factors and challenges existing in this market is important in coming up with effective strategies to improve diagnostic outcomes.
The factors responsible for driving the neglected tropical disease diagnosis market include:
• Increasing Global Focus on NTDs: The rise in the control of NTDs is associated with global health organizations and governments, which has led to more funding and support for diagnostic technologies. This leads to research that then improves the diagnosis tools and methods of disease management.
• Technological Advancements: Innovations such as Next-Generation Sequencing (NGS), Rapid Diagnostic Tests (RDTs), and Artificial Intelligence (AI) have improved diagnostic accuracy and efficiency. More accurate and timely disease detection is provided by these advances thus promoting market growth.
• Growing Demand for Accessible Diagnostics: There is a rising demand for affordable and accessible diagnostic solutions, especially in low-resource settings. For this reason, there has been a need to come up with lower-cost diagnostics that are more user-friendly towards reaching out to the underserved populations.
• Partnerships & Collaborations: Government, non-governmental organizations (NGOs) and private companies working together have led to development of new diagnostic tools. These coalitions increase resource availability while ensuring advancements in diagnostic technologies.
Challenges in the neglected tropical disease diagnosis market are:
• High Development Costs: Advanced molecular techniques-based diagnostics or those utilizing AI might be expensive to develop. In poor regions, their affordability could be limited because of high costs related to their development, production among others.
• Regulatory Hurdles: It can be time-consuming as well as complicated navigating through regulatory requirements required for clearing any new diagnostic tool. Regulatory challenges may delay market entry leading to an effect on new diagnostics’ availability.
• Limited Healthcare Infrastructure: In many places, particularly in low-resourced areas, inept healthcare infrastructure may impede the efficient application and utilization of diagnostic tools. This could be due to limited availability of skilled personnel and laboratories.
• Market Saturation: The entrance into the market by numerous diagnostic solutions providers as well as new companies makes differentiation for new players difficult and also reduces the success rate of their products.
Increasing global attention and advancement in technology are driving expansion in the NTD diagnostic market; however, this growth is challenged by high expenditures, regulatory difficulties and poor infrastructures which need a comprehensive approach if they are to have maximum effect on society.
List of Neglected Tropical Disease Diagnosis Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neglected tropical disease diagnosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neglected tropical disease diagnosis companies profiled in this report include-
• F. Hoffmann-La Roche
• Thermo Fisher Scientific
• InBios International
• Omega Diagnostics
• Oscar Medicare
• EUROIMMUN
• Novartis
• Grifols
• ZeptoMetrix
• DiaSys Diagnostic Systems
Neglected Tropical Disease Diagnosis by Segment
The study includes a forecast for the global neglected tropical disease diagnosis by disease type, method, service type, end use, and region.
Neglected Tropical Disease Diagnosis Market by Disease Type [Analysis by Value from 2018 to 2030]:
• Dengue
• Chikungunya
• Rabies
• Lymphatic Filariasis
• Buruli Ulcer
• Foodborne Trematodiases
• Echinococcosis
• Leprosy
• Others
Neglected Tropical Disease Diagnosis Market by Method [Analysis by Value from 2018 to 2030]:
• Conventional Method
• Molecular Method
Neglected Tropical Disease Diagnosis Market by Service Type [Analysis by Value from 2018 to 2030]:
• Centralized Service
• Point-of-Care Testing
Neglected Tropical Disease Diagnosis Market by End Use [Analysis by Value from 2018 to 2030]:
• Hospital and Clinic
• Home Healthcare
• Clinical Laboratories
• Others
Neglected Tropical Disease Diagnosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Neglected Tropical Disease Diagnosis Market
The current market for neglected tropical diseases (NTDs) diagnosis is in the midst of material changes as countries globally are stepping up their efforts to eradicate these diseases which are mostly forgotten. NTDs, comprising malaria, leprosy and lymphatic filariasis among others, mainly affect those with low socio-economic status living in the tropics and sub-tropics. The latest trends regarding the testing of such infections reveal disparity from one country to another based on national health care system, funding availability and research developments.
• United States: In the US, recent developments in NTD diagnosis have included integration of advanced molecular techniques like Next-Generation Sequencing (NGS) and CRISPR based diagnostics. Efforts are in progress to introduce rapid diagnostic tests that offer a good sensitivity as well as specificity for NTDs. Additionally, accessibility is being improved through collaborations between government agencies and the private sector, aimed at providing affordable diagnostic tools to underserved areas.
• China: China is developing affordable, high-throughput NTD diagnostics platforms to support their deployment into practice. Others include cost-effective PCR-based tests introduction as well as expansion of diagnostic services into rural regions. The Chinese government has been investing in R&D activities meant for improving diagnostic abilities while enhancing NTD surveillance so that early detection can be increased together with control measures.
• Germany: Novel diagnostic technologies for NTDs including multiplex assays simultaneously detecting multiple pathogens are being developed in Germany. The most recent advances comprise of high-resolution imaging combined with biosensors which enhance the speed together with accuracy in diagnostics. Research institutions from Germany also partner internationally in addressing global challenges related to NTDs while improving diagnosis-oriented low-resource setting approaches.
• India: In India major innovations made have been on point-of-care diagnostics for NTDs.Public health research has seen the production of portable diagnostic devices that can be used even in rural and remote areas. Diagnostic tools that are integrated with mobile health technologies are also being promoted in order to improve accessibility and data management, which is vital for effectively managing NTD outbreaks.
• Japan: In Japan there is investment toward better diagnosis of NTDs using advanced technology, with a focus on artificial intelligence (AI) integration and machine learning to improve the accuracy. For instance, AI-driven imaging systems and automated diagnostic platforms that streamline detection processes have been developed in recent times. Japan’s precision medicine approach promotes early disease detection and personalized treatment of NTDs.
Features of the Global Neglected Tropical Disease Diagnosis Market
Market Size Estimates: Neglected tropical disease diagnosis market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Neglected tropical disease diagnosis market size by various segments, such as by disease type, method, service type, end use, and region in terms of value ($B).
Regional Analysis: Neglected tropical disease diagnosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different disease types, methods, service types, end uses, and regions for the neglected tropical disease diagnosis market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neglected tropical disease diagnosis market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the growth forecast for neglected tropical disease diagnosis market?
Answer: The global neglected tropical disease diagnosis market is expected to grow with a CAGR of 4.9% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the neglected tropical disease diagnosis market?
Answer: The major drivers for this market are escalating number of overlooked tropical diseases, rising demand for rapid diagnostic tests and mounting recognition of ntds.
Q3. What are the major segments for neglected tropical disease diagnosis market?
Answer: The future of the neglected tropical disease diagnosis market looks promising with opportunities in the hospital and clinic, home healthcare, and clinical laboratory markets.
Q4. Who are the key neglected tropical disease diagnosis market companies?
Answer: Some of the key neglected tropical disease diagnosis companies are as follows:
• F. Hoffmann-La Roche
• Thermo Fisher Scientific
• InBios International
• Omega Diagnostics
• Oscar Medicare
• EUROIMMUN
• Novartis
• Grifols
• ZeptoMetrix
• DiaSys Diagnostic Systems
Q5. Which neglected tropical disease diagnosis market segment will be the largest in future?
Answer: Lucintel forecasts that dengue will remain the largest segment over the forecast period due to increasing adoption of point-of-care testing for dengue virus detection in developed nations.
Q6. In neglected tropical disease diagnosis market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest segment over the forecast period due to existence of skilled healthcare professionals and growing adoption of point-of-care testing services at home healthcare in the region.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Table of Contents 1. Executive Summary 2. Global Neglected Tropical Disease Diagnosis Market : Market Dynamics 2.1: Introduction, Background, and Classifications 2.2: Supply Chain 2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030) 3.2. Global Neglected Tropical Disease Diagnosis Market Trends (2018-2023) and Forecast (2024-2030) 3.3: Global Neglected Tropical Disease Diagnosis Market by Disease Type 3.3.1: Dengue 3.3.2: Chikungunya 3.3.3: Rabies 3.3.4: Lymphatic Filariasis 3.3.5: Buruli Ulcer 3.3.6: Foodborne Trematodiases 3.3.7: Echinococcosis 3.3.8: Leprosy 3.3.9: Others 3.4: Global Neglected Tropical Disease Diagnosis Market by Method 3.4.1: Conventional Method 3.4.2: Molecular Method 3.5: Global Neglected Tropical Disease Diagnosis Market by Service Type 3.5.1: Centralized Service 3.5.2: Point-of-Care Testing 3.6: Global Neglected Tropical Disease Diagnosis Market by End Use 3.6.1: Hospital and Clinic 3.6.2: Home Healthcare 3.6.3: Clinical Laboratories 3.6.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030 4.1: Global Neglected Tropical Disease Diagnosis Market by Region 4.2: North American Neglected Tropical Disease Diagnosis Market 4.2.1: North American Market by Form: Dispersion, Resin, and Membrane 4.2.2: North American Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others 4.3: European Neglected Tropical Disease Diagnosis Market 4.3.1: European Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others 4.3.2: European Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others 4.4: APAC Neglected Tropical Disease Diagnosis Market 4.4.1: APAC Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others 4.4.2: APAC Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others 4.5: ROW Neglected Tropical Disease Diagnosis Market 4.5.1: ROW Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others 4.5.2: ROW Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
5. Competitor Analysis 5.1: Product Portfolio Analysis 5.2: Operational Integration 5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis 6.1: Growth Opportunity Analysis 6.1.1: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Disease Type 6.1.2: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Method 6.1.3: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Service Type 6.1.4: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by End Use 6.1.5: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Region 6.2: Emerging Trends in the Global Neglected Tropical Disease Diagnosis Market 6.3: Strategic Analysis 6.3.1: New Product Development 6.3.2: Capacity Expansion of the Global Neglected Tropical Disease Diagnosis Market 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neglected Tropical Disease Diagnosis Market 6.3.4: Certification and Licensing
7. Company Profiles of Leading Players 7.1: F. Hoffmann-La Roche 7.2: Thermo Fisher Scientific 7.3: InBios International 7.4: Omega Diagnostics 7.5: Oscar Medicare 7.6: EUROIMMUN 7.7: Novartis 7.8: Grifols 7.9: ZeptoMetrix 7.10: DiaSys Diagnostic Systems